华森制药首季营收增速放缓至4.62% 控股股东时隔三个月再拟减持3%

Core Viewpoint - The controlling shareholder of Huason Pharmaceutical plans to reduce its stake again, indicating potential liquidity needs despite the company's stable fundamentals [1][3]. Group 1: Shareholder Reduction Plans - Chengdu Dijiang, the controlling shareholder, intends to reduce its holdings by up to 12.52 million shares, representing 3% of the total share capital, within three months from the announcement date [1]. - Executive Peng Xiaoyan also plans to sell up to 4,375 shares, which is 0.0010% of the total share capital [1]. - This marks the second reduction by the controlling shareholder within a year, with a previous reduction of the same amount completed between November 2024 and February 2025, resulting in proceeds of 14.7 million yuan [2]. Group 2: Company Performance - Huason Pharmaceutical reported a revenue of 775 million yuan in 2024, a year-on-year increase of 12.04%, and a net profit of 76.73 million yuan, up 134.66% [3]. - The growth is attributed to strong performance in traditional Chinese medicine products, with five exclusive Chinese patent medicines seeing a revenue increase of 21.71% [3]. - In Q1 2025, the company achieved a revenue of 239 million yuan, a 4.62% year-on-year growth, with net profits slightly increasing by 0.0098% [3][4]. Group 3: Market Dynamics - The revenue growth in Q1 2025 was slower due to a decrease in market demand compared to the previous year when flu cases were high, leading to increased sales of key products [4]. - Sales of the key product, Ganqi Bingmei Tablets, experienced a decline in revenue compared to the previous year, while other products like Liwei Anshen Capsules and Tongxie Ning Granules saw significant growth of 32.10% and 80.24%, respectively [4].